

Can multi-organ-on-a-chip technologies lead to a paradigm shift in drug development?

TissUse Head of BD to lead talk on the impact of Multi-organ-chip technologies on drug discovery.

LONDON, ENGLAND, UNITE, January 31, 2017

/EINPresswire.com/ -- TissUse, leading pioneers of the Multi-Organ-Chip technology, will be joining the [expert speaker lineup](#) for SMI Group's exclusive conference on [Drug Discovery](#). The event will be launched on the 27th and 28th of April 2017 in London.

TissUse's proprietary multi-organ-chip technology platform closely emulates and simulates human biology to achieve uniquely lifelike environments. Connected organs and close physiological context allow remarkably close resemblance to in vivo conditions. This has benefited the drug development process, with current in vitro and animal modelling tests failing to emulate physiological organ complexity within the human body.

Head of Business Development, Reyk Horland, will be leading a spotlight session on multi-organ-chip technologies and its potential impact on drug discovery at [the conference](#).

Reyk's presentation will showcase how "human-on-a-chip" technology is transforming drug development. He will demonstrate how this new approach allows us to closely study organoid interaction and allows more representative drug toxicity and efficacy screening. He will also highlight the importance of highly physiologically relevant cultures and microenvironments as scientists aim to close the gap between in vivo and in vitro.

Reyk will be speaking on Day 2 of the conference and joins lead decision-makers and industry innovators from Sanofi, Takeda, AstraZeneca, Merck Serono, AbbVie, GSK, Johnson & Johnson, UCB Pharma, Eli Lilly and more. A full list of speakers can be found on www.drug-discovery.co.uk/EIN.

SMi's Drug Discovery conference aims to bridge the gaps in approval for drug discovery and development by discussing the latest scientific breakthroughs, exploring novel technologies and approaches that can be used to overcome drug development challenges.

The event will also feature two post-conference workshops on new approaches in lead generation and applications of physicochemical and biomimetic properties in early drug discovery.

For more details about the conference and to register, visit www.drug-discovery.co.uk.



The poster for the Drug Discovery 2017 conference features a light blue background with a blurred image of laboratory glassware. At the top right is the SMI logo with the tagline 'SMI GROUP OF COMPANIES'. The main title 'DRUG DISCOVERY' is in large, bold, red letters. Below it, the dates '27 - 28 MARCH 2017' and location 'LONDON, UK' are in white. At the bottom, the website 'www.drug-discovery.co.uk' is displayed in white.

Drug Discovery 2017 | Register at www.drug-discovery.co.uk

DRUG DISCOVERY
27 – 28 MARCH 2017
Holiday Inn Kensington Forum
www.drug-design.co.uk

---end ---

Contact Information:

For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Fateja Begum at fbegum@smi-online.co.uk. For media queries please contact Honey de Gracia at hdegracia@smi-online.co.uk.

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Honey de Gracia
SMi Group Ltd
+44 (0)20 7827 6102
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2017 IPD Group, Inc. All Right Reserved.